PubRank

D H Gutmann

Author PubWeight™ 90.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992 4.42
2 The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev 2001 3.65
3 Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol 1997 2.28
4 Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001 2.13
5 cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991 2.03
6 Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 2009 2.00
7 Plexiform neurofibromas in NF1: toward biologic-based therapy. Neurology 2002 1.90
8 High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene 2008 1.84
9 Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet 2000 1.76
10 Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997 1.55
11 Cancer-related gene expression profiles in NF1-associated pilocytic astrocytomas. Neurology 2001 1.54
12 Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines. Nat Genet 1993 1.45
13 Differential effects of cAMP in neurons and astrocytes. Role of B-raf. J Biol Chem 1999 1.43
14 A conserved alternative splice in the von Recklinghausen neurofibromatosis (NF1) gene produces two neurofibromin isoforms, both of which have GTPase-activating protein activity. Mol Cell Biol 1993 1.43
15 Intracranial gliomas in neurofibromatosis type 1. Am J Med Genet 1999 1.29
16 Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 2000 1.27
17 Mammalian target of rapamycin: master regulator of cell growth in the nervous system. Histol Histopathol 2007 1.22
18 Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. J Neuropathol Exp Neurol 2001 1.21
19 Merlin differentially associates with the microtubule and actin cytoskeleton. J Neurosci Res 1998 1.21
20 Late-onset optic pathway tumors in children with neurofibromatosis 1. Neurology 2004 1.17
21 NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am J Pathol 2001 1.16
22 Merlin, DAL-1, and progesterone receptor expression in clinicopathologic subsets of meningioma: a correlative immunohistochemical study of 175 cases. J Neuropathol Exp Neurol 2000 1.16
23 Cervical cord compression from plexiform neurofibromas in neurofibromatosis 1. J Neurol Neurosurg Psychiatry 2007 1.14
24 Loss of neurofibromin is associated with activation of RAS/MAPK and PI3-K/AKT signaling in a neurofibromatosis 1 astrocytoma. J Neuropathol Exp Neurol 2000 1.14
25 Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. Neurology 2006 1.09
26 Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am J Med Genet 2000 1.09
27 The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol 2001 1.08
28 Identification of a progenitor cell of origin capable of generating diverse meningioma histological subtypes. Oncogene 2011 1.05
29 Expression of the neurofibromatosis I gene product, neurofibromin, in blood vessel endothelial cells and smooth muscle. Neurobiol Dis 1995 1.02
30 Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes. Glia 2001 0.99
31 Neurofibromatosis type 1 gene product (neurofibromin) associates with microtubules. Somat Cell Mol Genet 1993 0.99
32 The EWSR1/NR4A3 fusion protein of extraskeletal myxoid chondrosarcoma activates the PPARG nuclear receptor gene. J Pathol 2009 0.97
33 Tumorigenesis in neurofibromatosis: new insights and potential therapies. Trends Mol Med 2001 0.97
34 Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Neuroscience 2010 0.96
35 miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells. Oncogene 2012 0.95
36 The role of surgical biopsy in the diagnosis of glioma in individuals with neurofibromatosis-1. Neurology 2006 0.95
37 Ezrin, radixin, and moesin are components of Schwann cell microvilli. J Neurosci Res 2001 0.94
38 Mutations in the GAP-related domain impair the ability of neurofibromin to associate with microtubules. Brain Res 1997 0.94
39 Expression of the neurofibromatosis 2 tumor suppressor gene product, merlin, in Schwann cells. J Neurosci Res 1996 0.94
40 Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene 2006 0.93
41 Expression of a developmentally-regulated neuron-specific isoform of the neurofibromatosis 1 (NF1) gene. Neurosci Lett 1996 0.93
42 The tuberous sclerosis 2 gene is expressed at high levels in the cerebellum and developing spinal cord. Cell Growth Differ 1995 0.92
43 Expression of the tumor suppressor genes NF2, 4.1B, and TSLC1 in canine meningiomas. Vet Pathol 2009 0.92
44 Screening for symptomatic optic pathway glioma in children with neurofibromatosis type 1. Eye (Lond) 2011 0.89
45 The neurofibromatosis 2 tumor suppressor protein interacts with hepatocyte growth factor-regulated tyrosine kinase substrate. Hum Mol Genet 2000 0.88
46 Crosslinking of the surface immunoglobulin receptor in B lymphocytes induces a redistribution of neurofibromin but not p120-GAP. Oncogene 1994 0.87
47 Molecular analysis of malignant triton tumors. Hum Pathol 1999 0.87
48 Merlin: hanging tumor suppression on the Rac. Trends Cell Biol 2001 0.87
49 Regulation of mixed lineage kinase 3 is required for Neurofibromatosis-2-mediated growth suppression in human cancer. Oncogene 2010 0.87
50 Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. Int J Oncol 1999 0.86
51 Neurofibromatosis type 1: piecing the puzzle together. Can J Neurol Sci 1998 0.85
52 The ecology of brain tumors: lessons learned from neurofibromatosis-1. Oncogene 2010 0.85
53 Overexpression of bax in human glioma cell lines. J Neurosurg 1999 0.83
54 Tumor suppressor in lung cancer-1 (TSLC1) functions as a glioma tumor suppressor. Neurology 2006 0.83
55 Characterization and expression of H-21 region gene products on bone marrow-derived macrophages. Eur J Immunol 1982 0.83
56 Expression of the neurofibromatosis 1 (NF1) gene during growth arrest. Neuroreport 1996 0.82
57 Reduced TSC2 RNA and protein in sporadic astrocytomas and ependymomas. Ann Neurol 1997 0.81
58 Oculodentodigital dysplasia with cerebral white matter abnormalities in a two-generation family. Am J Med Genet 1995 0.81
59 Expression of the tuberous sclerosis 2 gene product, tuberin, in adult and developing nervous system tissues. Neurobiol Dis 1996 0.81
60 Genome-wide polymorphism analysis demonstrates a monoclonal origin of pilocytic astrocytoma. Neuropathol Appl Neurobiol 2011 0.81
61 Advances in neurofibromatosis 2 (NF2): a workshop report. J Neurogenet 2000 0.80
62 Expression of the neurofibromatosis 1 (NF1) gene in reactive astrocytes in vitro. Neuroreport 1995 0.80
63 Increased expression of the neurofibromatosis 1 (NF1) gene product, neurofibromin, in astrocytes in response to cerebral ischemia. J Neurosci Res 1996 0.80
64 Up-regulation of specific NF 1 gene transcripts in sporadic pilocytic astrocytomas. Am J Pathol 1996 0.80
65 Integrated MR imaging and proton nuclear magnetic resonance spectroscopy in a family with an X-linked spastic paraparesis. AJNR Am J Neuroradiol 1991 0.80
66 Juvenile xanthogranuloma, neurofibromatosis 1, and juvenile chronic myeloid leukemia. Arch Dermatol 1996 0.79
67 Major histocompatibility complex regulation of the immune response. J Surg Res 1985 0.79
68 The question of familial meningiomas and schwannomas: NF2B or not to be? Neurology 2000 0.79
69 An alternative apnea test for the evaluation of brain death. Ann Neurol 1991 0.79
70 Characterization of chicken Nf2/merlin indicates regulatory roles in cell proliferation and migration. Dev Dyn 2004 0.79
71 Neurofibromatosis 2 and malignant mesothelioma. Neurology 2002 0.79
72 Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. Neurosurg Focus 1997 0.78
73 Learning disabilities in neurofibromatosis 1: sizing up the brain. Arch Neurol 1999 0.78
74 Chromosome 11q23.3-qter deletion and Alexander disease. Am J Med Genet 1991 0.78
75 Ammonium acetate protocol for the preparation of plasmid DNA suitable for mammalian cell transfections. Biotechniques 1997 0.78
76 Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside. J Neurosurg 1998 0.77
77 Parent-of-origin in individuals with familial neurofibromatosis type 1 and optic pathway gliomas. Fam Cancer 2012 0.76
78 Tumor suppressor gene regulation of cell growth: recent insights into neurofibromatosis 1 and 2 gene function. Cell Biochem Biophys 2001 0.76
79 Specific expression of the neurofibromatosis type 1 gene (NF1) in the hamster Schwann cell. Am J Pathol 1994 0.76
80 In-vitro-derived bone marrow macrophages. Expression of Ia antigens during macrophage differentiation. Transplantation 1984 0.76
81 Review: low-grade gliomas as neurodevelopmental disorders: insights from mouse models of neurofibromatosis-1. Neuropathol Appl Neurobiol 2012 0.76
82 Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol 1999 0.75
83 Limitations of magnetic resonance spectroscopy in patients with white matter disease. Ann Neurol 1994 0.75
84 Comments on neurofibromatosis 1 and optic pathway tumors. Am J Med Genet 2001 0.75
85 Separation of the immune response genes for LDH-B and MOPC-173. I. Description of an immune response defect in B10.BASR1. J Immunol 1983 0.75
86 Acute presentation of a neurogenic sarcoma in a patient with neurofibromatosis type 1: a pathological and molecular explanation. Case report. J Neurosurg 1996 0.75
87 Separation of the immune response genes for LDH-B and MOPC-173. II. Description of an immune response defect in B10.ASR7. J Immunol 1984 0.75
88 Separation of the immune response genes for LDH-B and MOPC-173. III. Evidence that the failure of B10.BASR1 to respond to LDH-B is due to an antigen-presenting cell defect. Transplantation 1985 0.75
89 Restriction endonucleases. Am J Med Technol 1983 0.75
90 The use of restriction endonucleases in the prenatal diagnosis of hemoglobinopathies. Am J Med Technol 1982 0.75
91 Characterization of bone marrow derived macrophage as Ia-bearing accessory cells. Adv Exp Med Biol 1982 0.75
92 Symptomatic hydrocephalus and reversible spinal cord compression in Listeria monocytogenes meningitis. Case report. J Neurosurg 1989 0.75
93 Characterization of three new intra-I region recombinant mouse strains, B10.ASR7 (H-2as3), B10.BAR4 (H-2h6), and B10.BASR1 (H-2as4). Immunogenetics 1984 0.75
94 Establishing priorities in neurofibromatosis research: a workshop summary. Genet Med 2001 0.75
95 Pseudocervical cord syndrome: a deceptive flumazenil reversible manifestation of hepatic encephalopathy. Arch Neurol 1996 0.75
96 Cerebral vasculopathy and infarction in a woman with carcinomatous meningitis. J Neurooncol 1990 0.75